Skin cancer and Parkinson's disease.
Identifieur interne : 001A42 ( PubMed/Curation ); précédent : 001A41; suivant : 001A43Skin cancer and Parkinson's disease.
Auteurs : Joaquim J. Ferreira [Portugal] ; Dulce Neutel ; Tiago Mestre ; Miguel Coelho ; Mário M. Rosa ; Olivier Rascol ; Cristina SampaioSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2010.
English descriptors
- KwdEn :
- Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Breast Neoplasms (epidemiology), Breast Neoplasms (etiology), Female, Humans, Melanoma (chemically induced), Melanoma (epidemiology), Melanoma (etiology), Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Risk Factors, Skin Neoplasms (chemically induced), Skin Neoplasms (epidemiology), Skin Neoplasms (etiology), Thyroid Neoplasms (epidemiology), Thyroid Neoplasms (etiology).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents.
- chemical , adverse effects : Antiparkinson Agents.
- chemically induced : Melanoma, Skin Neoplasms.
- complications : Parkinson Disease.
- drug therapy : Parkinson Disease.
- epidemiology : Breast Neoplasms, Melanoma, Parkinson Disease, Skin Neoplasms, Thyroid Neoplasms.
- etiology : Breast Neoplasms, Melanoma, Skin Neoplasms, Thyroid Neoplasms.
- Female, Humans, Risk Factors.
Abstract
The report of an increased frequency of melanoma during the clinical development of rasagiline prompted a renewed interest in a possible association between skin cancer and Parkinson's disease (PD). The evaluation of this risk ended in a recommendation to perform a periodic dermatological examination as a follow-up measure of their treatment. The recognition of this safety concern lead to the need to clarify if the risk of skin cancer is indeed associated with PD and if levodopa or other anti-parkinsonian drugs might contribute to increase such risk. To answer these questions, we critically reviewed all clinical studies available concerning the association between skin cancer and PD. We found 26 studies on cancer occurrence in PD. The best data available suggest the risk of cancer is reduced in PD patients. However, specific cancers like thyroid and the female breast were reported at higher-than-expected rates. Additionally, it was suggested that PD patients have a higher frequency of melanoma and non-melanoma skin cancers than the general population. The data on non-melanoma skin cancer are less robust than the data on melanoma. Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening.
DOI: 10.1002/mds.22855
PubMed: 20063399
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001A42
Links to Exploration step
pubmed:20063399Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Skin cancer and Parkinson's disease.</title><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J" last="Ferreira">Joaquim J. Ferreira</name><affiliation wicri:level="1"><nlm:affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal. joaquimjferreira@net.sapo.pt</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon</wicri:regionArea></affiliation></author><author><name sortKey="Neutel, Dulce" sort="Neutel, Dulce" uniqKey="Neutel D" first="Dulce" last="Neutel">Dulce Neutel</name></author><author><name sortKey="Mestre, Tiago" sort="Mestre, Tiago" uniqKey="Mestre T" first="Tiago" last="Mestre">Tiago Mestre</name></author><author><name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name></author><author><name sortKey="Rosa, Mario M" sort="Rosa, Mario M" uniqKey="Rosa M" first="Mário M" last="Rosa">Mário M. Rosa</name></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="doi">10.1002/mds.22855</idno><idno type="RBID">pubmed:20063399</idno><idno type="pmid">20063399</idno><idno type="wicri:Area/PubMed/Corpus">001A42</idno><idno type="wicri:Area/PubMed/Curation">001A42</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Skin cancer and Parkinson's disease.</title><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J" last="Ferreira">Joaquim J. Ferreira</name><affiliation wicri:level="1"><nlm:affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal. joaquimjferreira@net.sapo.pt</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon</wicri:regionArea></affiliation></author><author><name sortKey="Neutel, Dulce" sort="Neutel, Dulce" uniqKey="Neutel D" first="Dulce" last="Neutel">Dulce Neutel</name></author><author><name sortKey="Mestre, Tiago" sort="Mestre, Tiago" uniqKey="Mestre T" first="Tiago" last="Mestre">Tiago Mestre</name></author><author><name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name></author><author><name sortKey="Rosa, Mario M" sort="Rosa, Mario M" uniqKey="Rosa M" first="Mário M" last="Rosa">Mário M. Rosa</name></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Breast Neoplasms (epidemiology)</term><term>Breast Neoplasms (etiology)</term><term>Female</term><term>Humans</term><term>Melanoma (chemically induced)</term><term>Melanoma (epidemiology)</term><term>Melanoma (etiology)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Risk Factors</term><term>Skin Neoplasms (chemically induced)</term><term>Skin Neoplasms (epidemiology)</term><term>Skin Neoplasms (etiology)</term><term>Thyroid Neoplasms (epidemiology)</term><term>Thyroid Neoplasms (etiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Melanoma</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Breast Neoplasms</term><term>Melanoma</term><term>Parkinson Disease</term><term>Skin Neoplasms</term><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Breast Neoplasms</term><term>Melanoma</term><term>Skin Neoplasms</term><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Risk Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The report of an increased frequency of melanoma during the clinical development of rasagiline prompted a renewed interest in a possible association between skin cancer and Parkinson's disease (PD). The evaluation of this risk ended in a recommendation to perform a periodic dermatological examination as a follow-up measure of their treatment. The recognition of this safety concern lead to the need to clarify if the risk of skin cancer is indeed associated with PD and if levodopa or other anti-parkinsonian drugs might contribute to increase such risk. To answer these questions, we critically reviewed all clinical studies available concerning the association between skin cancer and PD. We found 26 studies on cancer occurrence in PD. The best data available suggest the risk of cancer is reduced in PD patients. However, specific cancers like thyroid and the female breast were reported at higher-than-expected rates. Additionally, it was suggested that PD patients have a higher frequency of melanoma and non-melanoma skin cancers than the general population. The data on non-melanoma skin cancer are less robust than the data on melanoma. Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20063399</PMID><DateCreated><Year>2010</Year><Month>03</Month><Day>02</Day></DateCreated><DateCompleted><Year>2010</Year><Month>06</Month><Day>16</Day></DateCompleted><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Skin cancer and Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>139-48</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22855</ELocationID><Abstract><AbstractText>The report of an increased frequency of melanoma during the clinical development of rasagiline prompted a renewed interest in a possible association between skin cancer and Parkinson's disease (PD). The evaluation of this risk ended in a recommendation to perform a periodic dermatological examination as a follow-up measure of their treatment. The recognition of this safety concern lead to the need to clarify if the risk of skin cancer is indeed associated with PD and if levodopa or other anti-parkinsonian drugs might contribute to increase such risk. To answer these questions, we critically reviewed all clinical studies available concerning the association between skin cancer and PD. We found 26 studies on cancer occurrence in PD. The best data available suggest the risk of cancer is reduced in PD patients. However, specific cancers like thyroid and the female breast were reported at higher-than-expected rates. Additionally, it was suggested that PD patients have a higher frequency of melanoma and non-melanoma skin cancers than the general population. The data on non-melanoma skin cancer are less robust than the data on melanoma. Causal factors remain unknown. Due to the weak association between skin cancer and PD, no robust recommendation can be made regarding the need for periodic dermatological screening.</AbstractText><CopyrightInformation>(c) 2010 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Joaquim J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal. joaquimjferreira@net.sapo.pt</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neutel</LastName><ForeName>Dulce</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Mestre</LastName><ForeName>Tiago</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Coelho</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rosa</LastName><ForeName>Mário M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Sampaio</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001943">Breast Neoplasms</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008545">Melanoma</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012878">Skin Neoplasms</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013964">Thyroid Neoplasms</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>54</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22855</ArticleId><ArticleId IdType="pubmed">20063399</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A42 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001A42 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:20063399
|texte= Skin cancer and Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:20063399" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |